Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kytril vs Placebo for Delayed CINV Prevention
NCT00005024Phase 3Unknown
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in chemotherapy-induced nausea and vomiting (CINV) comparing Kytril Maintenance with Placebo Maintenance (2 arms). Primary endpoint: Efficacy in preventing nausea and vomiting during the 48 hours that begins 24 hours after administration of chemotherapy. Status: unknown.
02
Drugs
granisetron
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT00005024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005024.